Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 225

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial

Open access
Khan, Khurum H., Cunningham, David, Werner, Benjamin, Vlachogiannis, Georgios, Spiteri, Inmaculada, Heide, Timon, Mateos, Javier Fernandez, Vatsiou, Alexandra, Lampis, Andrea, Damavandi, Mahnaz Darvish, Lote, Hazel, Huntingford, Ian Said, Hedayat, Somaieh, Chau, Ian, Tunariu, Nina, Mentrasti, Giulia, Trevisani, Francesco, Rao, Sheela, Anandappa, Gayathri, Watkins, David, Starling, Naureen, Thomas, Janet, Peckitt, Clare, Khan, Nasir, Rugge, Massimo, Begum, Ruwaida, Hezelova, Blanka, Bryant, Annette, Jones, Thomas, Proszek, Paula, Fassan, Matteo, Hahne, Jens C., Hubank, Michael, Braconi, Chiara, Sottoriva, Andrea, Valeri, Nicola·2018·Cancer Discovery

Abstract

Sequential profiling of plasma cell-free DNA (cfDNA) holds immense promise for early detection of patient progression. However, how to exploit the predictive power of cfDNA as a liquid biopsy in the clinic remains unclear. RAS pathway aberrations can be tracked in cfDNA to monitor resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer. In this prospective phase II clinical trial of single-agent cetuximab in RAS wild-type patients, we combine genomic profiling of serial cfDNA and matched sequential tissue biopsies with imaging and mathematical modeling of cancer evolution. We show that a significant proportion of patients defined as RAS wild-type based on diagnostic tissue analysis harbor aberrations in the RAS pathway in pretreatment cfDNA and, in fact, do not benefit from EGFR inhibition. We demonstrate that primary and acquired resistance to cetuximab are often of polyclonal nature, and these dynamics can be observed in tissue and plasma. Furthermore, evolutionary modeling combined with frequent serial sampling of cfDNA allows prediction of the expected time to treatment failure in individual patients. This study demonstrates how integrating frequently sampled longitudinal liquid biopsies with a mathematical framework of tumor evolution allows individualized quantitative forecasting of progression, providing novel opportunities for adaptive personalized therapies. Significance: Liquid biopsies capture spatial and temporal heterogeneity underpinning resistance to anti-EGFR monoclonal antibodies in colorectal cancer. Dense serial sampling is needed to predict the time to treatment failure and generate a window of opportunity for intervention. Cancer Discov; 8(10); 1270–85. ©2018 AACR. See related commentary by Siravegna and Corcoran, p. 1213. This article is highlighted in the In This Issue feature, p. 1195

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-17-0891

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 225

Metadata

Authors
Khan, K. H., Cunningham, D., Werner, B., Vlachogiannis, G., Spiteri, I., Heide, T., Mateos, J. F., Vatsiou, A., Lampis, A., Damavandi, M. D., Lote, H., Huntingford, I. S., Hedayat, S., Chau, I., Tunariu, N., Mentrasti, G., Trevisani, F., Rao, S., Anandappa, G., Watkins, D., Starling, N., Thomas, J., Peckitt, C., Khan, N., Rugge, M., Begum, R., Hezelova, B., Bryant, A., Jones, T., Proszek, P., Fassan, M., Hahne, J. C., Hubank, M., Braconi, C., Sottoriva, A., & Valeri, N.
Venue
Cancer Discovery
Published
2018-10-01
Volume
8
Issue
10
Pages
1270-1285
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2889264838
Cited by
225
References
19
FWCI
9.08
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. https://app.cochat.ai/papers/10.1158/2159-8290.cd-17-0891
The paper
Khan, K. H., Cunningham, D., Werner, B., Vlachogiannis, G., Spiteri, I., Heide, T., Mateos, J. F., Vatsiou, A., Lampis, A., Damavandi, M. D., Lote, H., Huntingford, I. S., Hedayat, S., Chau, I., Tunariu, N., Mentrasti, G., Trevisani, F., Rao, S., Anandappa, G., . . . Valeri, N. (2018). Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-17-0891

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.